Home > Focus Areas > Type 2 Diabetes Connect > Post
  • Saved

7mo
What’s New in T2D? Highlights from the 2025 ADA Guidelines

The 2025 ADA guidelines introduce key updates that reflect the growing need for personalized, comprehensive diabetes care to address a broader patient population. Among the most notable changes, continuous glucose monitoring (CGM) is now recommended beyond insulin-treated individuals, particularly for adults with type 2 diabetes who are on glucose-lowering therapies who may benefit from real-time glucose insights to improve glycemic control and reduce variability. The guidelines also offer strategies to navigate medication shortages, incorporate additional classes of glucose-lowering agents with cardiovascular and renal benefits, and maintain weight-loss pharmacotherapy beyond initial goals to support long-term metabolic health.

As medication selection continues to evolve, the guidelines emphasize a patient-centered approach that prioritizes cardiovascular, renal, and metabolic health. Beyond glucose lowering, clinicians are encouraged to consider therapy combinations with demonstrated benefits in reducing cardiovascular risk, slowing kidney disease progression, and supporting sustained weight management. New cardiovascular findings reinforce the role of SGLT2 inhibitors, expanding their use in both preserved and reduced ejection fraction heart failure. The guidelines likewise encourage careful patient selection and ongoing monitoring for adverse effects. Additionally, lifestyle-based interventions such as structured nutrition plans, physical activity, and behavioral strategies remain core pillars in achieving metabolic targets.

How will these updates shape your management strategies for adults with type 2 diabetes, particularly in integrating advanced monitoring tools and optimizing heart and kidney protection?

  • 7mo
    continous glucose monitoring prevents severe hypoglcemia and hyperglycemia
  • 7mo
    The 2025 ADA guidelines emphasize a more personalized approach to type 2 diabetes care. CGM is now recommended for more patients, including those not on insulin, to improve glycemic control. There’s a stronger focus on early use of SGLT2 inhibitors and GLP-1 receptor agonists for heart and kidney protection. Long-term use of weight-loss medications is encouraged to maintain metabolic health. Clinicians are advised to navigate medication shortages thoughtfully and continue to prioritize lifestyle changes as core to treatment. Overall, the guidelines support a broader, proactive strategy beyond just lowering blood sugar.
  • 8mo
    sglt 2 inhibitors are very useful to help improve multiple comorbidities and CGM use will help keep our diabetiics better controlled
  • 8mo
    I've been practicing that way for a while now, so I would like to do a better job at focusing on small lifestyle changes that can make a big difference in the long run. SGLT2 meds are great and effective not just to lower A1C but do that while protecting the renal and cardiovascular systems.
  • 8mo
    SGLT2 inhibitors continue to provide benefits for T2DM patients with not only A1c reduction but also reducing progression of CKD and proteinuria as well as reducing exacerbation and hospitalizations from Heart Failure. Along with CGM, diabetes will become easier to control and improve quality of life for patients that suffer from this condition
  • 8mo
    Cgm will gradually be used also in noninsulin dependent diabetes and SGLT2i will increase in use as well as new coming oral GLP1RA analogues
  • 8mo
    I agree with the summarized statements and guidelines wholeheartedly, however, while initiating every DM2 patient on CGM as part of their therapy is an extremely valuable treatment option, insurance companies do not seem to agree. I also agree SGLT-2s offer many advantages in one treatment option not previously seen in others. I have begun to prescribe these medications earlier in the algorithm than in recent years, and hopefully, with these guidleines, insurance companies will allow them to be used first line more often for appropriate patients, prior to metformin.
  • 8mo
    Although the treatment landscape of DM2 continues to expand, the treatment of DM2 become simpler with the three main choices of therapeutics: SGLT2, GLP-1 and metformin. Unfortunately, insurance guidelines present unnecessary barriers for the institution of CGMs.
  • 8mo
    We are at a privileged place in today's medical practice that we are able to look at comorbidities in our patients with T2DM and make choices for GLP-1RAs, SGLt2is with proven cardio-renal-metabolic benefits & self-management strategies and valuable information from CGMs.
  • 8mo
    We are at a privileged place in today's medical practice that we are able to look at comorbidities in our patients with T2DM and make choices for GLP-1RAs, SGLt2is with proven cardio-renal-metabolic benefits & self-management strategies and valuable information from CGMs.
  • 8mo
    I use SGLT2 inhibitors; Ozempic and Kerendia in patients with DM and CKD as all these agents have proven benefits in reducing progression of CKD and decreasing cardiovascular mortality in these patients. I frequently use CGM in patients wit Type 2 diabetes especially ones on Insulin but also patients not on Insulin therapy unless their insurance denies it.
  • 8mo
    The current treatment plan for me will be more use of CGM , further risk assesments for renal and cardiovascular and implementation of SGLT-2 more frequent and earlier.

    Since i also like mounjaro over ozempic for better weight reduction, better hgaic control and better tolerability i will add the sglt-2 early for the added benefits.
  • 8mo
    continous glucose monitoring for patients results in better care able patient to stay at goals in glycemia control
  • 9mo
    CGMs , GLPs
  • 9mo
    CGMs are the biggest revolution in the management of Diabetes and with their biofeedback has resulted in positive outcomes with behavior modification diet and exercise and now with OTC avaialability of them has gone to a different dimension altogether with patient being incharge of their glycemic control and gives the providers better and timely management and trouble shooting in optimal control at the same time SGLT-2 inhibitors initially introduced as diabetic meds have become the standard of care in CAD , CHF and CKD patients So the question we have to ask ourselves in management of T2D , CKD and CAD and CHF pts is why they can not be on SGLT-2 inhibitors as in these pts optimal consdierations should be given to get the pts on these meds ! great time to practice diabetology and for Primary Care with these meds and the tools their role has become more important and effective also minmizing the referrals to endo and have the opportunity to have the broad spectrum perspective of Cardiac and Renal Health as well !!!
  • 9mo
    more data on benefit in type 1 as well
  • 9mo
    sglt2 and kerendia are excellent for stopping microalbunia and ckd
  • 9mo
    SGLT-2 inhibitors are medication with multiple indications, prevent progression ckd, decrease the risk of cardiovascular events, the use of uACR and gfr are improtant in the monitoring ckd, adjust treatment .

Show More Comments